Trial
NCT05716347
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Collaborators
—
Condition
COVID-19
Intervention
the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Why stopped
Company strategy adjustment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-28